Complex Hereditary Spastic Paraplegia (HSP): Comprehensive Research Report

1. Disease Information

Overview. Hereditary spastic paraplegia (HSP) is not a single disease but a large, clinically and genetically heterogeneous group of inherited neurodegenerative disorders whose unifying pathological feature is retrograde ("dying-back"), length-dependent axonal degeneration of the corticospinal tracts (and often the dorsal columns), producing progressive lower-limb spasticity and weakness (MedLink Neurology; PMC6827077). HSPs are clinically split into: - Pure (uncomplicated) HSP — progressive spastic paraplegia with hyperreflexia, extensor plantar responses (Babinski sign), and urinary urgency/bladder dysfunction as essentially the only findings (GeneReviews NBK1509). - Complex (complicated) HSP — spastic paraplegia plus additional neurological features (ataxia, peripheral neuropathy, epilepsy, intellectual disability/cognitive decline, extrapyramidal signs/parkinsonism, optic atrophy, retinopathy, deafness) and/or non-neurological systemic features (dysmorphism, skeletal deformity, skin changes) (PMC4939695; PMC8749458).

More than 88 spastic paraplegia (SPG) gene loci have been described, with 40+ confirmed causal genes, spanning autosomal dominant (AD), autosomal recessive (AR), X-linked, and (rarely) mitochondrial inheritance (PMC8662366; Pharos disease page). Complex forms are disproportionately autosomal recessive, with SPG11 (spatacsin), SPG15/ZFYVE26 (spastizin), SPG7 (paraplegin), SPG5A/CYP7B1, SPG35/FA2H, SPG20 (Troyer syndrome), and the AP-4 complex disorders (SPG47/50/51/52) among the most frequent/best characterized complex etiologies.

Key identifiers. - Pharos lists "complex hereditary spastic paraplegia" as a distinct disease-concept entry (Pharos). - There is no single unifying MONDO/OMIM ID for "complex HSP" as a category — it is a cross-cutting clinical descriptor applied across dozens of individually MONDO/OMIM-coded SPG subtypes. Representative examples: pure-or-complex AD spastic paraplegia group MONDO:0008438; AR complex spastic paraplegia (SPG23) MONDO:0010046; pure-or-complex AR spastic paraplegia (SPG48) MONDO:0013342 (search aggregation). - Individual OMIM entries exist per subtype, e.g., SPG3A OMIM #182600, SPG5A OMIM #270800, SPG7 OMIM #607259, SPG12 OMIM #604805 (OMIM). - Orphanet groups HSP under ORPHA:99013 ("Hereditary spastic paraplegia"), with individual ORPHA codes per numbered SPG subtype and clinical form (pure vs. complicated). - ICD-10: G11.4 (hereditary spastic paraplegia); ICD-11: 8A02.1. - MeSH: D015419 (Spastic Paraplegia, Hereditary).

Synonyms: Familial spastic paraplegia; Strümpell-Lorrain disease/syndrome; hereditary spastic paraparesis; French settlement disease (historical); "complicated"/"complex" HSP.

Evidence base: Predominantly aggregated disease-level literature (case series, natural-history cohorts, genetic-diagnostic cohorts) rather than large-scale EHR studies, though a few population-based epidemiologic studies exist (Norway, England/Northern Ireland; see Section 9) (PMC12210554).

2. Etiology

Primary cause: Monogenic — pathogenic variants in one of >88 SPG loci disrupting core cell-biological processes in long CNS axons (see Section 6). Genetic architecture, not environmental exposure, is the dominant causal factor; complex forms are enriched for AR inheritance and biallelic loss-of-function alleles.

Genetic risk factors: - Causal, highly penetrant variants in SPAST (SPG4), ATL1 (SPG3A), REEP1 (SPG31) account for pure HSP; SPAST/ATL1/REEP1 together account for well over 50% of all HSP (JCI PMC2846052). - Complex/recessive HSP causal genes: SPG11 (spatacsin) — most prevalent AR complex HSP gene (~8% of registered AR HSP cases) (Frontiers/PMC search synthesis); SPG15/ZFYVE26; SPG7 (paraplegin); CYP7B1 (SPG5A); FA2H (SPG35); SPG20 (spartin, Troyer syndrome); AP4B1/AP4M1/AP4E1/AP4S1 (SPG47/50/51/52). - Consanguinity is a strong risk-enrichment factor for AR complex HSP, particularly in Mediterranean and Middle Eastern populations with high consanguinity rates (PMC8944001). - Modifier genes/digenic inheritance: recent work reports digenic SPG7/AFG3L2 interactions modulating motor neuron and cerebellar phenotypes (medRxiv preprint, 2025) (medRxiv).

Environmental/risk modifiers: No established environmental or infectious causal contributors; age at onset and severity are influenced by genotype (see Section 8) rather than known exposures. No consistent sex-ratio skew has been reported ("no differences in rate relating to gender were found") (PMC8944001).

Protective factors: None well established at the population level; some evidence that later disease onset in certain genotypes (e.g., SPG3A vs. SPG4) correlates with slower progression, which may reflect allelic/genetic background effects rather than a true protective factor (Springer natural history).

Gene-environment interaction: Not a major feature of this disease group; HSP is considered predominantly monogenic with modifier-gene (not environmental) modulation of expressivity.

3. Phenotypes

Core "pure" phenotype (present in virtually all HSP, complex or pure)

Frequencies above from a large SPG4/SPAST-HSP cohort (Neurology Genetics NXG.0000000000000664).

Complex-form additional phenotypes (by representative subtype)

Age of onset / progression / severity: Highly variable — from congenital/infantile (AP-4-HSP) to childhood (SPG11, SPG35) to adult/late-onset (SPG4, SPG7, SPG3A), with mean HSP onset age around 24 years across pooled cohorts (PMC8944001). Complex forms tend to progress faster than pure forms: Spastic Paraplegia Rating Scale (SPRS) annual progression ~1.3 points/year in complicated HSP vs. 0.6 points/year in pure HSP (Austrian natural history cohort, Springer 2025). Disease severity/progression is genotype-dependent: SPG11 carries the highest severity burden; SPG3A tends to progress more slowly than SPG4 (same source).

Quality of life: Direct QoL instrument data specific to HSP is sparse in the literature surveyed; management studies report substantial impact on mobility/independent ambulation and increased psychiatric comorbidity (anxiety/depression) documented in the England/N. Ireland epidemiologic cohort (PMC12210554).

4. Genetic/Molecular Information

Causal genes (selected, complex-form-relevant): | Gene | HGNC | Locus/OMIM | Protein | Inheritance | |---|---|---|---|---| | SPAST | HGNC:11233 | SPG4, OMIM #182601 | Spastin (microtubule-severing AAA-ATPase) | AD | | ATL1 | HGNC:30288 | SPG3A, OMIM #182600 | Atlastin-1 (ER-shaping GTPase) | AD | | REEP1 | HGNC:13703 | SPG31 | REEP1 (ER-shaping hairpin protein) | AD | | SPG11 | HGNC:11226 | SPG11, OMIM #604360 | Spatacsin | AR | | ZFYVE26 | HGNC:29128 | SPG15 | Spastizin | AR | | SPG7 | HGNC:11237 | SPG7, OMIM #607259 | Paraplegin (m-AAA mitochondrial protease subunit) | AR (occasionally digenic w/ AFG3L2) | | CYP7B1 | HGNC:2652 | SPG5A, OMIM #270800 | Oxysterol 7α-hydroxylase | AR | | FA2H | HGNC:20139 | SPG35 | Fatty acid 2-hydroxylase | AR | | SPART (SPG20) | HGNC:11227 | SPG20 (Troyer syndrome) | Spartin | AR | | AP4B1 | HGNC:567 | SPG47 | AP-4 complex β subunit | AR | | AP4M1 | HGNC:569 | SPG50 | AP-4 complex μ subunit | AR | | AP4E1 | HGNC:568 | SPG51 | AP-4 complex ε subunit | AR | | AP4S1 | HGNC:571 | SPG52 | AP-4 complex σ subunit | AR |

Pathogenic variant types: Loss-of-function (nonsense, frameshift, splice-site) predominates in AR complex forms (e.g., SPG11, SPG20, AP-4 genes are essentially null alleles: "the pathogenesis of Troyer syndrome results from a loss-of-function mechanism" rather than a toxic truncated protein) (Wikipedia SPG20 synthesis). Missense variants with dominant-negative or haploinsufficient effects predominate in AD pure forms (SPAST, ATL1). Variant classification should follow ACMG/AMP criteria via ClinVar/ClinGen; allele frequencies for pathogenic variants are characteristically rare/absent in gnomAD, consistent with a rare Mendelian disease, though specific founder alleles exist in consanguineous/isolate populations.

Functional consequences: - Spastin: loss of microtubule-severing activity → disrupted axonal microtubule dynamics/transport. - Atlastin-1/REEP1: loss of ER tubule-fusion/shaping activity, disrupting the tubular ER network's coordination with microtubules in long axons (PMC2846052). - Spatacsin/spastizin (SPG11/SPG15): loss of AP-5-adaptor accessory function → defective lysosomal reformation/tubulation and autophagosome-lysosome fusion, causing autophagosome/enlarged-lysosome accumulation (PMC4078876). - Paraplegin (SPG7): loss of m-AAA mitochondrial protease function → mitochondrial proteostasis failure, permeability-transition-pore dysregulation, ATPase deficiency (Lancet eBioMedicine). - CYP7B1: loss of oxysterol 7α-hydroxylase activity → toxic accumulation of 25- and 27-hydroxycholesterol, which are neurotoxic and blood-brain-barrier permeable (ScienceDirect; PubMed 18252231). - AP-4 complex subunits: loss of AP-4-mediated vesicular sorting (notably ATG9A trafficking) → autophagy-initiation defects; Ap4b1-knockout mice show "ATG9A mislocalization" (PMC9825813).

Modifier genes: AFG3L2 as a digenic modifier/co-causal partner with SPG7 in some motor neuron/cerebellar presentations (medRxiv 2025).

Epigenetics/chromosomal abnormalities: Not a prominent feature of HSP pathogenesis in the literature surveyed; disease is driven by point/small indel variants in nuclear-encoded genes rather than large chromosomal rearrangements or a described episignature.

5. Environmental Information

No specific toxin, infectious agent, or lifestyle exposure has been causally linked to HSP; the searched literature identifies HSP as a purely genetic disease group. Environmental/behavioral factors have not been studied as HSP risk modifiers in the sources reviewed. This section is largely not applicable for this Mendelian disease class beyond noting that catabolic stress or intercurrent illness is not a described trigger (in contrast to some other neurogenetic disease classes in this KB, e.g., metabolic intoxication disorders).

6. Mechanism / Pathophysiology

Core convergent pathophysiology: Regardless of causal gene, HSP mechanistically converges on length-dependent ("dying-back") retrograde axonal degeneration of the corticospinal tract (and often dorsal columns), because these are the longest axons in the human CNS (up to ~1 m) and are maximally dependent on efficient long-range organelle/cargo transport and membrane maintenance (PMC6827077). "The central nervous system's long axons are hotspots and the first site of hereditary spastic paraplegia axonopathy."

Major convergent molecular pathway clusters (from PMC8004882 and PMC6031053):

1. ER shaping / membrane trafficking (SPAST, ATL1, REEP1 axis). Atlastin-1 (a GTPase) mediates homotypic fusion of ER tubules to form three-way junctions of the tubular ER network; it physically interacts with spastin (microtubule-severing AAA-ATPase) and REEP1 (a hairpin ER-shaping protein), and this tripartite complex "coordinate[s] microtubule interactions with the tubular ER network" specifically within long corticospinal axons (JCI, PubMed 20200447). Loss of any one component destabilizes ER-microtubule coupling, impairing axonal ER distribution and organelle transport.
2. Lysosomal/autophagosome maturation (SPG11/SPG15 axis). Spatacsin (SPG11) and spastizin (SPG15) form a complex, cooperating with the AP-5 adaptor complex in late-endosome/lysosome membrane sorting; loss of function causes defective autophagosome-to-lysosome fusion, lysosome depletion, and enlarged/dysfunctional lysosomes, driving neurodegeneration with the distinctive thin-corpus-callosum, cognitive, and retinal phenotype (PMC4078876; PMC4540459). A 2024 zebrafish spastizin model additionally shows axon demyelination and degeneration, implicating oligodendrocyte/myelin dysfunction as a downstream mechanism (bioRxiv/PMC11539067).
3. Mitochondrial quality control (SPG7 axis). Paraplegin, part of the mitochondrial inner-membrane m-AAA protease, is required for mitochondrial protein quality control and ribosome assembly; its loss causes ATPase deficiency, impaired permeability-transition-pore "flickering," and secondary anterograde/retrograde axonal transport failure, producing progressive distal axonopathy of spinal and peripheral nerves that faithfully recapitulates the human SPG7 phenotype in Spg7-knockout mice (Lancet eBioMedicine).
4. Cholesterol/oxysterol metabolism (CYP7B1/SPG5A axis). Loss of oxysterol 7α-hydroxylase blocks the alternative bile-acid synthesis pathway, causing toxic accumulation of 25- and 27-hydroxycholesterol, which cross the blood-brain barrier and are directly neurotoxic to corticospinal and dorsal-column axons (ScienceDirect).
5. Complex sphingolipid/myelin lipid metabolism (FA2H/SPG35 axis). Loss of fatty acid 2-hydroxylase impairs synthesis of 2-hydroxylated sphingolipids required for normal myelin composition, producing a leukodystrophy-like phenotype with white-matter abnormalities, sometimes overlapping neurodegeneration with brain iron accumulation (the entity is also called fatty acid hydroxylase-associated neurodegeneration, FAHN) (PMC6238570; PubMed 38353247).
6. AP-4 vesicular sorting (SPG47/50/51/52 axis). Loss of any AP-4 complex subunit disrupts anterograde sorting of ATG9A (an autophagy-initiation transmembrane protein) from the trans-Golgi network, impairing autophagosome biogenesis; Ap4b1-knockout mice show motor dysfunction, aberrant brain morphology, and ATG9A mislocalization, closely mirroring the profound infantile/childhood-onset human phenotype (PMC9825813).
7. Non-cell-autonomous glial mechanism. Emerging evidence (in vitro/model organism) implicates impaired lipid/cholesterol homeostasis in astrocytes as a non-cell-autonomous driver of cortical projection-neuron degeneration in HSP, expanding the mechanism beyond a purely neuron-intrinsic model (PMC7720406).
8. Lipid metabolism broadly. A dedicated review ("Lipids in the Physiopathology of Hereditary Spastic Paraplegias") frames disrupted lipid/membrane metabolism (cholesterol, sphingolipids, phospholipids) as a unifying downstream theme across many complex-HSP genes (PMC7059351).

Suggested GO terms: GO:0007018 (microtubule-based movement), GO:0016183 (ER tubular network organization), GO:0007009 (plasma membrane organization) → more precisely GO:0071786 (ER tubular network organization), GO:0006914 (autophagy), GO:0007009, GO:1902774 (late endosome to lysosome transport), GO:0007005 (mitochondrion organization), GO:0034599 (cellular response to oxidative stress), GO:0008203 (cholesterol metabolic process), GO:0030149 (sphingolipid catabolic process), GO:0007041 (lysosomal transport).

Suggested CL terms: CL:0000029 (corticospinal tract upper motor neuron)/CL:0011005 (corticospinal neuron), CL:0000030 (glutamatergic neuron, alt.), CL:0000127 (astrocyte, for the non-cell-autonomous glial mechanism), CL:0000128 (oligodendrocyte, for SPG15 demyelination).

Causal chain summary (generalized template for a complex-HSP disorder node): Gene-specific lesion (e.g., biallelic SPG11 loss-of-function) → organelle-specific dysfunction (lysosomal/autophagic dysfunction) → impaired long-axon maintenance (corticospinal + additional tract/structure involvement, e.g., corpus callosum, cerebellum, retina) → length-dependent retrograde axonal degeneration → progressive spasticity plus complex-form-specific extra-pyramidal features (cognitive decline, ataxia, retinopathy, etc.).

7. Anatomical Structures Affected

Organ/system level: - Primary: central nervous system — corticospinal tracts (upper motor neuron), often dorsal (posterior) spinal columns. - Secondary (complex forms): cerebellum (ataxia), corpus callosum (SPG11/15 thinning), peripheral nerves (neuropathy — SPG7, AP-4 disorders), optic nerve (atrophy — SPG7), retina (pigmentary retinopathy — SPG11/15), lens (cataracts — SPG11/15), skeletal system (pes cavus, scoliosis, short stature — SPG20), bladder (neurogenic bladder/urgency), white matter broadly (leukodystrophy — SPG35).

Tissue/cell level (Cell Ontology): - CL:0011005 corticospinal neuron / CL:0000029 (upper motor neuron parent term via UBERON:0002240 spinal cord) - CL:0000127 astrocyte (non-cell-autonomous mechanism) - CL:0000128 oligodendrocyte (myelin/demyelination component) - CL:0000540 neuron (general) - Retinal photoreceptor cells (SPG11/15 retinopathy) - Peripheral sensory/motor neurons (SPG7, AP-4 neuropathy)

Subcellular level (GO Cellular Component): - GO:0005783 endoplasmic reticulum (tubular ER; SPAST/ATL1/REEP1) - GO:0005739 mitochondrion, specifically GO:0005743 mitochondrial inner membrane (SPG7 m-AAA protease) - GO:0005764 lysosome / GO:0005776 autophagosome (SPG11/SPG15, AP-4) - GO:0005874 microtubule / GO:0015630 microtubule cytoskeleton - GO:0030134 COPII-coated ER-to-Golgi transport vesicle (AP-4-related Golgi sorting)

Localization (UBERON): - UBERON:0002240 (spinal cord), UBERON:0001133 (corticospinal tract), UBERON:0002756 (corpus callosum), UBERON:0002037 (cerebellum), UBERON:0000966 (retina), UBERON:0000970 (eye), UBERON:0001021 (nerve/peripheral nervous system). - Lateralization: HSP motor findings are typically bilateral and symmetric (a distinguishing feature from unilateral corticospinal lesions of other etiologies).

8. Temporal Development

Onset: Ranges continuously from congenital/infantile (AP-4-HSP: global developmental delay from infancy) through childhood (SPG11 median onset in the first two decades; SPG35 childhood-onset with seizures/leukodystrophy) to adult-onset (SPG4, SPG7 — onset can occur "as late as age 72 years" for SPG7) (PMC8793673). Mean HSP onset across pooled cohorts ≈ 24 years (PMC8944001). SPG5A median onset ~13 years (range 1–63) (Elsevier).

Onset pattern: Insidious/chronic-progressive in essentially all forms; not acute or episodic.

Progression: - Generally slow but genotype-dependent; overall SPRS progression ~0.9 points/year pooled, but 1.3 points/year in complicated HSP vs. 0.6 points/year in pure HSP (Springer 2025). - SPG11 carries higher severity and a more rapid course, with "limited lifespan of 3 to 4 decades after disease-onset" reported in some cohorts and rapid deterioration described in Dutch SPG11 cohorts (PMC3798836). - Loss of independent ambulation: variable — from within 1–2 decades of onset to intact ambulation after 24 years in milder genotypes; later age at onset is paradoxically associated with faster loss of independent walking in some analyses. - SPG3A tends to progress more slowly than SPG4. - AP-4-HSP: children who achieve independent walking typically lose this ability months to a few years later as hypotonia converts to hypertonia/spasticity (Boston Children's Hospital).

Disease course pattern: Chronic, progressive, non-remitting (not relapsing-remitting or episodic). No spontaneous-remission pattern is described.

Critical periods: For the AP-4 disorders and other infantile-onset complex forms, early diagnosis is critical because gene-therapy intervention windows are being defined pre-symptomatically or in very early disease (see Section 12) — the SPG50 trial specifically dosed a pre-symptomatic 5-month-old alongside symptomatic children to test whether earlier intervention alters outcome (CGTlive).

9. Inheritance and Population

Epidemiology: - Pooled global HSP prevalence estimates: 2–7.4/100,000 across most populations, with a range of 0.1–9.6/100,000 reported worldwide and modeling estimates converging around 3.6/100,000 overall (PMC8944001). - Genotype-specific global prevalence estimates: SPG4 ≈ 0.90/100,000; SPG7 ≈ 0.22/100,000; SPG11 ≈ 0.34/100,000; SPG15 ≈ 0.13/100,000 (BMC Neurology, Springer). - Norway (population >2.5M): prevalence 7.4/100,000 (2009 study) — among the highest reported. - Spain: ~2.24/100,000 (lower). - Higher prevalence reported in Mediterranean/Middle Eastern populations with high consanguinity. - Incidence in England/Northern Ireland rose from 0.12/100,000 person-years (2000) to 0.29/100,000 person-years (2021) (PMC12210554) — likely reflecting improved genetic diagnosis rather than true incidence increase.

Inheritance pattern: All classical Mendelian modes reported — AD (SPG3A, SPG4, SPG31, SPG12), AR (SPG5A, SPG7, SPG11, SPG15, SPG20, SPG35, AP-4 disorders SPG47/50/51/52), X-linked (e.g., SPG1/L1CAM, SPG2/PLP1), and rare mitochondrial-associated presentations.

Penetrance/expressivity: AD forms (SPAST, ATL1) show high but sometimes age-dependent penetrance and marked intra-familial variable expressivity (age of onset and severity can differ substantially between relatives carrying the same variant). AR complex forms are generally fully penetrant when biallelic loss-of-function variants are present, given the severe cellular consequences (e.g., near-complete loss of AP-4 complex function).

Genetic anticipation: Not a characteristic feature of HSP (unlike repeat-expansion disorders); HSP genes are not repeat-expansion loci in the mainstream classification.

Consanguinity: A major risk-enrichment factor for AR complex HSP; complex AR forms are relatively more frequent in populations/regions with high consanguinity rates.

Founder effects: Population-specific founder alleles have been described for several SPG genes in isolated/consanguineous populations (implicit in the geographic prevalence variation, though the sources reviewed did not enumerate specific founder variants in detail).

Population demographics: No described sex-ratio skew; age at onset varies as above by genotype; geographic distribution shows Mediterranean/Middle Eastern enrichment for consanguinity-associated AR complex subtypes and higher Norwegian/Northern European prevalence for AD pure forms.

10. Diagnostics

Clinical exam/tests: - Neurological exam: lower-limb spasticity, hyperreflexia, Babinski sign, clonus, pes cavus. - MRI brain/spine: thin corpus callosum (SPG11/15 — a key distinguishing neuroimaging clue), white-matter/leukodystrophic changes (SPG35), cerebellar atrophy (SPG7), "ears of the lynx" sign (classically associated with SPG11/15 thin corpus callosum + periventricular white matter changes). - Ophthalmologic exam: optic disc pallor/atrophy (SPG7), retinal pigmentary changes (SPG11/15), cataract exam. - Nerve conduction studies/EMG: to detect peripheral neuropathy component in complex forms (SPG7, AP-4 disorders). - Urodynamic studies for neurogenic bladder assessment. - Biochemical: elevated serum/CSF 25- and 27-hydroxycholesterol as a diagnostic/monitoring biomarker specific to SPG5A/CYP7B1 (ScienceDirect).

Genetic testing: - Recommended approach: Given >90 implicated genes, next-generation sequencing gene panels are the recommended cost-effective first-line test; a representative panel (SpastiSure3.0) covers 118 HSP-associated genes. - Diagnostic yield: Overall genetic diagnosis achieved in ~29–31% of clinically suspected pediatric HSP cohorts using panel testing; yield rises with age-stratified analysis (up to 37% in ages 0–5 when panel is followed by exome) (Human Genomics, Springer). Diagnostic rate is markedly inheritance-pattern-dependent: 56.7% in AD HSP, 55.5% in AR HSP, but only 21.2% in sporadic HSP cases, and overall diagnostic gap of ~25% remains even in the best-studied cohorts. - Whole exome sequencing (WES): Recommended when panel testing is negative, particularly for complicated/complex phenotypes; "exome sequencing is a useful diagnostic tool for complicated forms of hereditary spastic paraplegia" (PubMed 23438842); WES clearly benefits children with suspected HSP when panels are non-diagnostic (PMC13040777). - Chromosomal microarray/karyotype: not first-line, as HSP is overwhelmingly a single-gene/small-variant disease rather than a copy-number/structural disorder, though CNV analysis is sometimes included in comprehensive panels.

Clinical diagnostic criteria: No single formal DSM/ICD-based criteria set beyond the clinical pure-vs-complex classification described above; diagnosis rests on clinical phenotype plus molecular confirmation, given marked genetic heterogeneity and phenocopy overlap with other upper-motor-neuron disorders (differential diagnosis includes primary lateral sclerosis, multiple sclerosis, dopa-responsive dystonia, cerebral palsy [static, non-progressive — a key distinguishing feature], vitamin B12/E deficiency, and adrenomyeloneuropathy).

Screening: No population-based newborn or carrier screening program specific to HSP; genetic counseling and cascade testing are recommended in families with a known pathogenic variant, particularly for AR complex forms in consanguineous families.

11. Outcome/Prognosis

Survival/mortality: HSP itself is not typically directly life-limiting in pure/adult-onset forms; however, severe complex forms (notably SPG11) are associated with reduced functional lifespan — "limited lifespan of 3 to 4 decades after disease-onset" in some SPG11 cohorts — reflecting cumulative disability and complications rather than the spasticity itself being acutely fatal ([derived from natural history literature above]).

Morbidity/function: - Progressive loss of independent ambulation is the dominant functional endpoint; timing is highly genotype-dependent (see Section 8). - SPRS (Spastic Paraplegia Rating Scale) is the standard longitudinal functional/severity outcome measure, with annual progression rates of ~0.6 (pure) to ~1.3 (complicated) points/year. - Complex-form comorbidities (cognitive decline, ataxia, visual impairment from retinopathy/optic atrophy, neurogenic bladder, orthopedic deformity) compound disability beyond the pure motor phenotype. - Increased burden of common mental health outcomes (anxiety, depression) documented in a large England/Northern Ireland epidemiologic cohort of HSP patients (PMC12210554).

Complications: Contractures, scoliosis/orthopedic deformity, neurogenic bladder/urinary tract complications, falls/fractures from gait instability, and (in complex forms) seizures, visual impairment, and cognitive decline.

Recovery potential: No spontaneous recovery; disease-modifying interventions are only now emerging (gene therapy — Section 12) and remain investigational/single-patient/early-phase.

Prognostic factors: Genotype is the dominant prognostic factor (SPG11 = more severe/faster; SPG3A = slower than SPG4); age at onset; presence of complex-form features generally predicts faster SPRS progression than pure HSP.

12. Treatment

Current standard of care: There is no disease-modifying therapy approved for the great majority of HSP subtypes; management is symptomatic and multidisciplinary ("symptomatic management should be multidisciplinary to achieve better control of motor symptoms... and prevent skeletal deformities") (Merck Manual; PMC10858081).

Pharmacotherapy (symptomatic): - Antispastic agents: baclofen (first-line), tizanidine, diazepam, clonazepam, dantrolene — MAXO/NCIT: NCIT:C15986 Pharmacotherapy, with therapeutic_agent CHEBI baclofen (CHEBI:2942), tizanidine. - Botulinum toxin type A/B (BTX-A/BTX-B) — intramuscular injection for focal spasticity; reduces spasticity and fatigue without affecting depression/excessive daytime sleepiness; combined BTX + intensive physiotherapy shows added benefit (PMC7046620; recent comprehensive 2025 review, PMC12567745). MAXO/NCIT: could map to NCIT:C1198 (Botulinum Toxin) as therapeutic_agent under Pharmacotherapy. - Oxybutynin for urinary urgency/neurogenic bladder. - Historical clinical-trial pharmacologic agents (mostly negative or inconclusive for disease modification): atorvastatin, gabapentin, L-threonine, dalfampridine (4-aminopyridine), methylphenidate (PMC9321931). - SPG5A/CYP7B1-specific: atorvastatin + chenodeoxycholic acid (± resveratrol) trialed to normalize elevated 25-/27-hydroxycholesterol and restore bile-acid profile; a randomized controlled trial (Schöls et al., Brain 2017, PMID 29126212) found atorvastatin reduced serum 27-OHC/25-OHC (though CSF 27-OHC reduction was not significant) (PubMed 29126212).

Advanced/gene-targeted therapeutics (investigational, complex-HSP-specific): - SPG50 (AP4M1) gene therapy: Intrathecal AAV9/AP4M1 gene replacement. A single-patient phase 1 trial (NCT06069687) dosed a 4-year-old boy intrathecally with 1×10¹⁵ vg AAV9-AP4M1 in March 2022 — among the largest AAV9 CSF doses ever given — with 12-month follow-up showing apparent disease-course stabilization and no serious adverse events (Nature Medicine 2024, PMC11271397). Elpida Therapeutics' "Melpida" program (NCT05518188, Phase I/II) has since dosed additional participants (ages 3–5 years at 1×10�1⁵ vg; a pre-symptomatic 5-month-old at 4×10¹⁴ vg), with FDA clearance to proceed to a Phase III trial (8 children, initiated August 2024) (Clinical Trials Arena; CGTlive). Preclinical AAV9/AP4M1 work established safety/efficacy in mouse models first (PMC10178841). - SPG47 (AP4B1) gene therapy: Preclinical AAV9-hAP4B1 delivered into the cisterna magna in a mouse model, with "restoration of various hallmarks of disease" (PMC11554807); patient-advocacy-driven programs coordinated via Cure AP-4/Cure SPG47 foundations. - SPG5 (CYP7B1) gene therapy: AAV8-based gene-replacement therapy in preclinical development (PMC12309954); an mRNA-based therapeutic strategy for SPG5 has also been proposed (Molecular Therapy Methods & Clinical Development, Cell.com). - Modality classification: therapeutic_modality: GENE_THERAPY for the AAV programs above (AAV9/AAV8 capsid, intrathecal or intra-cisterna-magna delivery, gene-replacement mechanism — not gene editing).

Surgical/interventional: Orthopedic surgery for severe contractures/scoliosis; intrathecal baclofen pump for refractory severe spasticity; selective dorsal rhizotomy considered in select cases (extrapolated from general spasticity-management literature, not HSP-specific data in the sources reviewed).

Supportive/rehabilitative: - Physical therapy/exercise: maintains mobility, muscle strength, range of motion, reduces fatigue and spasms (MAXO:0000011 physical therapy) — non-pharmacological systematic review (2023) supports benefit (PMC10858081; Springer). - Occupational therapy, orthotics (ankle-foot orthoses for foot drop/pes cavus), gait aids/wheelchairs as disease progresses. - Emerging modality: radial extracorporeal shock wave therapy reported efficacious in an HSP case report (PMC12338253).

Experimental (clinical trials): Natural history/biomarker studies (NCT02859428 for SPG3A/SPG4/SPG31; SPG5 natural history/RCT [PubMed 29126212]); NCT04712812 registry/natural history study for early-onset HSP; the SPG50 gene-therapy trials above.

Treatment strategy: No formal disease-specific treatment algorithm exists analogous to oncology guidelines; management is individualized/multidisciplinary (neurology, physiatry/rehabilitation, urology, orthopedics, ophthalmology for complex forms, genetics/genetic counseling). Personalized/genotype-guided approaches are emerging specifically for SPG5A (biochemical-pathway-targeted therapy) and the AP-4 disorders/SPG50 (gene replacement).

13. Prevention

Primary prevention: Not applicable in the traditional sense (no modifiable risk-factor exposure to eliminate); the only "primary prevention" avenue is reproductive risk reduction via genetic counseling, carrier screening, and preimplantation genetic diagnosis (PGD) in families with a known pathogenic variant, particularly relevant for AR complex forms in consanguineous unions.

Secondary prevention: Early molecular diagnosis (panel/WES) to enable early initiation of symptomatic/supportive management and, increasingly, eligibility screening for investigational gene therapy (the SPG50 program explicitly enrolled a pre-symptomatic infant to test whether earlier intervention alters the trajectory).

Tertiary prevention: Prevention of secondary complications — regular physical therapy/stretching to prevent contractures, orthopedic surveillance for scoliosis, urological surveillance for bladder complications, ophthalmologic monitoring in complex forms with retinal/optic involvement.

Genetic counseling: Central to management in families with identified variants — risk assessment for future pregnancies, cascade testing of at-risk relatives, and discussion of reproductive options (PGD, prenatal testing) given the autosomal recessive predominance of complex HSP and the consanguinity risk factor.

Public health/behavioral/immunization/prophylaxis: Not applicable — no described environmental, infectious, or vaccine-preventable component to this disease group.

14. Other Species / Natural Disease

The literature reviewed focused on induced/engineered models (Section 15) rather than naturally occurring veterinary HSP. No spontaneous naturally-occurring canine/feline/equine HSP orthologous disease was identified in the sources searched (unlike some other neurogenetic disorders with well-documented veterinary natural disease counterparts). This section is likely not well populated for this disease from available searches; a targeted OMIA search would be needed to confirm whether any spontaneous animal spastic paraplegia orthologs are catalogued (not performed here due to no hits surfacing in general search).

Orthologous genes (NCBI Gene, for model-organism cross-reference): Spast (mouse Gene ID: 232265), Atl1 (mouse), Spg7 (mouse Gene ID: 105875), Ap4b1 (mouse), Ap4m1 (mouse), Spg20/Spart (mouse) — all with characterized knockout mouse models (below).

15. Model Organisms

Mouse models (most extensively characterized): - Spg7−/− (paraplegin-null) mouse: Progressive motor impairment from ~4.5 months of age; retrograde axonal degeneration of long descending (corticospinal) and ascending (dorsal column) spinal tracts plus peripheral and optic nerves; early appearance of ultrastructurally abnormal mitochondria in affected axons, worsening with age. Explicitly stated to "successfully recapitulate the key phenotypic and pathological features observed in SPG7 patients" (PMC5628248 synthesis; PMC7469654). - Ap4b1-knockout mouse (SPG47 model): Motor dysfunction, aberrant brain morphology, and ATG9A mislocalization, providing mechanistic and preclinical-therapeutic validation for the AAV9-hAP4B1 gene-therapy program (PMC9825813). - Spg20−/− mouse (Troyer syndrome model): Reveals multimodal spartin functions in lipid-droplet maintenance, cytokinesis, and BMP signaling — expanding the mechanistic understanding of spartin beyond a single pathway (PMC3406757). - SPG50 preclinical AAV9/AP4M1 efficacy studies were conducted in a corresponding Ap4m1 mouse model prior to human dosing (PMC10178841).

Zebrafish models: - Spastizin (SPG15/ZFYVE26) zebrafish model: Shows axon demyelination and degeneration, extending the disease-relevant phenotype into a myelin-dysfunction axis not previously emphasized in mammalian models — a 2024 bioRxiv/PMC study (PMC11539067).

Cellular/iPSC and patient-derived models: - Patient-derived fibroblasts (SPG11, SPG15) show autophagosome accumulation and enlarged lysosomes, directly demonstrating defective autophagosome-lysosome fusion in a human cellular context (PMC4078876). - iPSC-derived neuronal models comparing SPG7 vs. SPAST patient-derived stem cells show that mitochondrial functional deficits are specific to SPG7, not SPAST, patient cells — an important cross-genotype mechanistic distinction (title: "Mitochondrial Function in Hereditary Spastic Paraplegia: Deficits in SPG7 but Not SPAST Patient-Derived Stem Cells") (PMC7469654). - Patient-derived fibroblasts were also used directly for translational validation of AAV2/AP4M1 gene-therapy vectors prior to the human SPG50 trial (phenotypic rescue demonstrated in vitro).

Model limitations: Mouse Spg7 and Ap4b1 knockouts recapitulate core motor/axonal-degeneration phenotypes reasonably well, but full complex-HSP multisystem features (e.g., human-specific cognitive/retinal phenotypes in SPG11/15) are less completely captured in rodent models — this is consistent with the general caveat that mouse CNS models often under-represent human-specific cortical/cognitive phenotypes. Zebrafish models add a demyelination phenotype not otherwise emphasized in mouse data, suggesting species-dependent phenotypic emphasis.

Applications: These models have been directly used for (a) mechanistic dissection of the axonal-transport/ER/mitochondrial/lysosomal/autophagy pathways described in Section 6, and (b) as the essential preclinical efficacy/safety platform for the AAV gene-therapy programs now in human trials for SPG47 and SPG50.

Summary Table: Suggested Ontology Terms for KB Curation

Sources

• Genetic and phenotypic characterization of complex hereditary spastic paraplegia (PMC4939695)
• Insights into Clinical, Genetic, and Pathological Aspects of HSP: A Comprehensive Overview (PMC8662366)
• A complex form of HSP harboring p.W1515* in SPG11 (PMC8749458)
• Hereditary Spastic Paraplegia: An Update (PMC8835766)
• AP-4-Associated HSP – GeneReviews (NBK535153)
• Uncomplicated (Pure) HSP Overview – GeneReviews (NBK1509)
• Spastic Paraplegia 11 – GeneReviews (NBK1210)
• Hereditary Spastic Paraplegia: From Genes, Cells and Networks to Novel Pathways for Drug Discovery (PMC8004882)
• Ascending Axonal Degeneration of the Corticospinal Tract in Pure HSP: DTI Study (PMC6827077)
• Impaired lipid metabolism in astrocytes underlies degeneration of cortical projection neurons in HSP (PMC7720406)
• Axon demyelination and degeneration in a zebrafish spastizin model of HSP (PMC11539067)
• Lysosomal abnormalities in HSP types SPG15 and SPG11 (PMC4078876)
• In Vivo Evidence for Lysosome Depletion and Impaired Autophagic Clearance in SPG11 (PMC4540459)
• Janus-faced spatacsin (SPG11), Brain 2020
• Impaired mitochondrial dynamics underlie axonal defects in HSP (PMC6031053)
• REEP1, spastin, atlastin-1 coordinate microtubule interactions with tubular ER network – PMID 20200447 / PMC2846052
• Global epidemiology of hereditary ataxia and spastic paraplegia – PMID 24603320
• An integrated modelling methodology for estimating global incidence/prevalence of SPG4/7/11/15 (PMC8944001)
• Epidemiology of HSP and mental health outcomes in England/N. Ireland (PMC12210554)
• Natural history in HSP: Austrian cohort, J Neurol 2025 (PMC12835074)
• Rapidly deteriorating course in Dutch SPG11 patients (PMC3798836)
• HSP type 5: natural history, biomarkers, RCT – PMID 29126212
• Cure AP-4 / Cure SPG47 Foundation
• Pre-clinical AP4B1 gene replacement therapy for SPG47 (PMC11554807)
• Intrathecal AAV9/AP4M1 gene therapy for SPG50, preclinical (PMC10178841)
• AAV gene therapy for HSP type 50: phase 1 single-patient trial, Nature Medicine (PMC11271397)
• Elpida Therapeutics Phase III SPG50 trial announcement
• SPG50 Gene Therapy Warrants Further Study (CGTlive)
• The Neuro-Ophthalmologic Manifestations of SPG7-Associated Disease (PMC12565430)
• Impaired flickering of the permeability transition pore causes SPG7 spastic paraplegia (eBioMedicine)
• Mitochondrial Function in HSP: Deficits in SPG7 but Not SPAST Patient-Derived Stem Cells (PMC7469654)
• Ap4b1-knockout mouse model of SPG47 (PMC9825813)
• Elevated hydroxycholesterols in Norwegian SPG5 patients
• Sequence alterations within CYP7B1 – PMID 18252231
• AAV8-based gene replacement therapy for HSP type 5 (PMC12309954)
• mRNA as a Novel Treatment Strategy for HSP Type 5 (Cell.com)
• Mutation of FA2H underlies SPG35 – PMID 20104589
• HSP type 35 with novel FA2H mutation, literature review (PMC6238570)
• SPG20/Spartin – Wikipedia synthesis
• Spg20−/− mice reveal multimodal functions for spartin (PMC3406757)
• Clinical-Genetic Features Influencing Disability in SPG4 (Neurology Genetics)
• Children with suspected HSP benefit from whole exome analysis (Human Genomics, Springer)
• Exome sequencing diagnostic tool for complicated HSP – PMID 23438842
• Non-pharmacological treatment of HSP: systematic review (PMC10858081)
• Botulinum Toxin Treatment in HSP — Comprehensive Review (PMC12567745)
• Efficacy of combined botulinum toxin + intensive physiotherapy in HSP (PMC7046620)
• The Puzzle of HSP: From Epidemiology to Treatment (PMC9321931)
• Lipids in the Physiopathology of HSPs (PMC7059351)
• Pharos: complex hereditary spastic paraplegia disease page
• OMIM #182600 SPG3A, OMIM #270800 SPG5A, OMIM #604805 SPG12

1. Disease Information

Overview

Complex hereditary spastic paraplegia (complex HSP, also termed "complicated HSP") is a heterogeneous group of rare, inherited neurodegenerative disorders characterized by progressive lower-limb spasticity due to corticospinal tract degeneration, combined with additional neurological and non-neurological manifestations that distinguish it from "pure" or "uncomplicated" HSP (meyyazhagan2022thepuzzleof pages 1-2, meyyazhagan2022hereditaryspasticparaplegia pages 1-2). These additional features may include intellectual disability, seizures, dementia, cerebellar ataxia, peripheral neuropathy, optic atrophy, dysarthria, extrapyramidal disturbances, and skeletal deformities (meyyazhagan2022hereditaryspasticparaplegia pages 1-2). Complex HSP represents approximately 55% of HSP cases in some cohorts, highlighting its significant contribution to the overall HSP spectrum (amprosi2026naturalhistoryin pages 1-2).

Key Identifiers

• MONDO ID: MONDO:0015150 (complex hereditary spastic paraplegia) (OpenTargets Search: hereditary spastic paraplegia)
• MONDO ID (parent): MONDO:0019064 (hereditary spastic paraplegia)
• Orphanet: ORPHA:100987 (complex hereditary spastic paraplegia)
• ICD-10: G11.4 (Hereditary spastic paraplegia)
• ICD-11: 8A60.1
• MeSH: D015419 (Spastic Paraplegia, Hereditary)

Synonyms

Common synonyms include: complicated hereditary spastic paraplegia, complex HSP, complicated spastic paraplegia, HSP-plus, and complicated familial spastic paraplegia (meyyazhagan2022thepuzzleof pages 1-2, yu2023clinicalfeaturesand pages 1-2).

2. Etiology

Disease Causal Factors

Complex HSP is caused primarily by monogenic mutations in genes affecting neuronal function, with over 90 genetic loci (designated SPG1–SPG83+) identified to date (meyyazhagan2022hereditaryspasticparaplegia pages 2-4, cipriano2025fluidbiomarkersin pages 1-2). The disorder is exclusively genetic in origin, with mutations in approximately 80 genes affecting diverse biochemical pathways including lipid droplet formation, endoplasmic reticulum (ER) shaping, axonal transport, endosome trafficking, and mitochondrial function (meyyazhagan2022thepuzzleof pages 1-2).

Genetic Risk Factors

Complex forms of HSP are most commonly autosomal recessive (AR), in contrast to pure HSP which is more often autosomal dominant (AD) (fereshtehnejad2023movementdisordersin pages 4-5). In a systematic review and meta-analysis of 1,413 HSP cases with movement disorders, AR inheritance was present in 58.4% and AD in 31.4% (fereshtehnejad2023movementdisordersin pages 4-5). Consanguinity is a major risk factor, particularly for AR forms such as SPG11, where consanguinity odds ratio was 4.1 compared to SPG7 (fereshtehnejad2023movementdisordersin pages 5-6). In the MENA region, SPG11 (19.8%), FA2H (8.5%), and ZFYVE26 (7.7%) were the most frequently identified genes, with AR HSP with thin corpus callosum being common (meyyazhagan2022thepuzzleof pages 1-2).

Environmental and Gene-Environment Interactions

Complex HSP is fundamentally a genetic disorder, and no specific environmental risk factors have been established as causal. However, environmental modifiers and gene-environment interactions remain poorly characterized. Lifestyle factors such as physical activity level may influence symptom severity and functional decline, but specific data are lacking.

3. Phenotypes

The following table summarizes the major phenotypic features of complex HSP with associated frequencies and HPO terms:

Table: This table summarizes major clinical and imaging features reported in complex hereditary spastic paraplegia, emphasizing frequencies from recent cohorts—especially SPG15 and pediatric-onset complex HSP. It is useful for phenotype-driven diagnosis, ontology mapping, and genotype-phenotype curation.

Detailed Phenotypic Characteristics

Age of Onset: Complex HSP typically presents earlier than pure HSP. In a pediatric-onset Japanese cohort, the median age of onset for complex-type was 16 months (IQR 12–26 months) (ikeda2023geneticandclinical pages 3-4). For SPG15, symptom onset occurred at a median of 24 months with developmental symptoms preceding motor manifestations by several years (saffari2023theclinicaland pages 1-2, saffari2023theclinicaland pages 3-5). In adult-onset movement disorder cases, mean age of onset was 20.5 ± 16.0 years (fereshtehnejad2023movementdisordersin pages 4-5).

Symptom Progression: The disease is progressive, with spasticity initially affecting distal lower limbs before progressing proximally (saffari2023theclinicaland pages 1-2). In SPG15, loss of independent ambulation occurred at a mean age of 17 years, with wheelchair dependency developing by mean age 20 years (saffari2023theclinicaland pages 8-9). An Austrian natural history study demonstrated complicated HSP progresses faster than pure HSP (1.3 vs. 0.6 SPRS points/year; p < 0.001) (amprosi2026naturalhistoryin pages 1-2, amprosi2026naturalhistoryin pages 13-14).

Quality of Life Impact: Complex HSP significantly impairs quality of life, with modified Rankin Scale scores significantly higher in complex-type (3.5 ± 1.0) compared to pure-type HSP (2.1 ± 0.9; p < 0.001) (ikeda2023geneticandclinical pages 3-4). The progressive nature leads to walking cane or wheelchair dependence over time. In the Austrian cohort, 17.5% of patients were wheelchair-bound, while over 50% did not require assistive devices (amprosi2026naturalhistoryin pages 11-13). Although HSP does not typically reduce lifespan, it significantly impairs quality of life, particularly with more severe symptoms (awuah2024hereditaryspasticparaplegia pages 1-2). However, some complex forms such as SPG11 are associated with restricted life expectancy (chojdakłukasiewicz2023hereditaryspasticparaplegia pages 4-6).

4. Genetic/Molecular Information

Causal Genes

The following table provides a comprehensive overview of the major genes associated with complex HSP:

Table: This table summarizes the major genes implicated in complex hereditary spastic paraplegia, highlighting inheritance, encoded proteins, and distinguishing clinical features. It is useful for comparing the most important SPG subtypes and related complex HSP genes across the heterogeneous disease spectrum.

Most Common Genetic Subtypes

In AD HSP (80% of North American and Northern European populations), SPG4/SPAST accounts for 40% of cases, SPG3A/ATL1 for 10%, SPG31/REEP1 for 10%, and SPG10/KIF5A for 3% (meyyazhagan2022hereditaryspasticparaplegia pages 12-14). Among AR forms, SPG11 and SPG15 are the most significant complex HSP subtypes, along with SPG35/FA2H, SPG45/C19orf12, and SPG7 (5–12% of AR cases) (meyyazhagan2022hereditaryspasticparaplegia pages 12-14). In a Chinese cohort, SPAST was the most common gene, followed by SPG11 and ATL1 (yu2023clinicalfeaturesand pages 1-2). In pediatric complex HSP, KIF1A variants were the most common cause (ikeda2023geneticandclinical pages 3-4).

Pathogenic Variants

Pathogenic variants span multiple types including missense, frameshift, nonsense, splice-site, and structural variants (large deletions/duplications) (meyyazhagan2022hereditaryspasticparaplegia pages 4-6, meyyazhagan2022thepuzzleof pages 5-6). For SPG15, 45 distinct ZFYVE26 variants have been described, distributed across the protein structure without mutational hotspots (saffari2023theclinicaland pages 1-2). SPG4 variants include both point mutations and exon deletions detectable by MLPA (meyyazhagan2022thepuzzleof pages 5-6). Variant classification follows ACMG-AMP 2015 guidelines (saffari2023theclinicaland pages 13-13). All variants are germline in origin.

Inheritance Patterns

Complex HSP follows all major Mendelian inheritance patterns: autosomal recessive (most common for complex forms), autosomal dominant, X-linked recessive (SPG1/L1CAM, SPG2/PLP1), and mitochondrial inheritance (meyyazhagan2022hereditaryspasticparaplegia pages 2-4, meyyazhagan2022hereditaryspasticparaplegia pages 12-14). Variable expressivity is characteristic, and penetrance varies by gene and variant.

5. Environmental Information

Complex HSP is not associated with established environmental risk factors, infectious agents, or specific lifestyle factors as causative agents. The disease is exclusively genetic in etiology. No gene-environment interactions have been validated, though physical activity and rehabilitation may influence functional outcomes.

6. Mechanism / Pathophysiology

Molecular Pathways

The pathophysiology of complex HSP involves disruption of multiple interconnected cellular pathways (awuah2024hereditaryspasticparaplegia pages 1-2, meyyazhagan2022hereditaryspasticparaplegia pages 14-16):

Endoplasmic Reticulum Morphogenesis and Membrane Trafficking: Mutations in ER-associated proteins (spastin/SPG4, atlastin/SPG3A, REEP1/SPG31) disrupt ER tubular network formation and ER-microtubule relationships, which are critical for axonal maintenance (meyyazhagan2022hereditaryspasticparaplegia pages 14-16, meyyazhagan2022thepuzzleof pages 2-5). GO terms: GO:0030176 (ER tubular network organization); GO:0016197 (endosome transport).

Autophagy-Lysosomal Pathway: Spatacsin (SPG11) and spastizin (SPG15/ZFYVE26) are essential for autophagic lysosome reformation. Their dysfunction leads to impaired autophagosome-lysosome fusion and accumulation of lysosomal structures (awuah2024hereditaryspasticparaplegia pages 8-10, vijayaraghavan2025roleofglial pages 2-3). AP-4 complex mutations (SPG47, SPG50, SPG51, SPG52) cause mislocation of ATG9A, a key autophagy protein (wiseman2024preclinicaldevelopmentof pages 13-15). GO terms: GO:0006914 (autophagy); GO:0005764 (lysosome).

Mitochondrial Dysfunction: Loss of paraplegin/AFG3L2 complex impairs ATP production and increases vulnerability to reactive oxygen species (awuah2024hereditaryspasticparaplegia pages 2-4). Disrupted mitochondrial fission-fusion dynamics causes impaired axonal transport, oxidative phosphorylation deficiencies, and axonal degeneration (awuah2024hereditaryspasticparaplegia pages 2-4, meyyazhagan2022thepuzzleof pages 12-14). GO terms: GO:0005739 (mitochondrion); GO:0006119 (oxidative phosphorylation).

Lipid Metabolism: Defects in lipid droplet formation, cholesterol metabolism (CYP7B1/SPG5), fatty acid hydroxylation (FA2H/SPG35), and phospholipid regulation (PNPLA6/SPG39) compromise neuronal membrane integrity and myelin maintenance (meyyazhagan2022thepuzzleof pages 1-2, vijayaraghavan2025roleofglial pages 2-3, meyyazhagan2022thepuzzleof pages 11-12). AMFR mutations cause lipid droplet accumulation in neural stem cells (garg2024divingdeepzebrafish pages 5-6). GO terms: GO:0006629 (lipid metabolic process); GO:0005811 (lipid droplet).

Axonal Transport and Microtubule Dynamics: Spastin (SPG4) is a microtubule-severing enzyme; its dysfunction causes microtubule disorganization and impaired axonal transport (meyyazhagan2022hereditaryspasticparaplegia pages 14-16, meyyazhagan2022thepuzzleof pages 12-14). KIF1A and KIF5A mutations directly affect kinesin-mediated axonal transport (garg2024divingdeepzebrafish pages 5-6). GO terms: GO:0007018 (microtubule-based movement); GO:0008088 (axo-dendritic transport).

Myelination Abnormalities: PLP1 (SPG2) mutations and L1CAM (SPG1) mutations reduce myelin protein expression and impair oligodendrocyte function, limiting myelin maintenance of corticospinal neurons (awuah2024hereditaryspasticparaplegia pages 8-10). GO terms: GO:0042552 (myelination).

Glial Cell Involvement

Recent research has revealed a non-cell-autonomous mechanism in HSP, with impaired lipid metabolism and reduced lipid droplets in HSP astrocytes contributing to axonal degeneration of cortical neurons (vijayaraghavan2025roleofglial pages 2-3). Reactive astrocytes produce both cytotoxic molecules (LCN2, IL-1β, TNF-α, nitric oxide) and neuroprotective factors (BDNF, NGF), while increased microgliosis and pro-inflammatory factors have been observed in HSP patient samples (vijayaraghavan2025roleofglial pages 2-3). CL terms: CL:0000127 (astrocyte); CL:0000129 (microglial cell); CL:0000540 (neuron).

Causal Chain

The primary trigger is a germline genetic mutation → protein loss-of-function or dysfunction → disruption of one or more core cellular pathways (ER morphogenesis, autophagy, mitochondrial function, lipid metabolism, axonal transport) → selective vulnerability of long corticospinal tract axons due to their high metabolic demands → progressive axonal degeneration → neuronal dysfunction and cell death → clinical manifestation of progressive spasticity and additional neurological features (awuah2024hereditaryspasticparaplegia pages 1-2, meyyazhagan2022thepuzzleof pages 2-5).

7. Anatomical Structures Affected

Organ Level

• Primary: Central nervous system, specifically the corticospinal tracts (lateral columns of thoracic and cervical spinal cord) (UBERON:0002187)
• Secondary: Cerebellum (UBERON:0002037), cerebral cortex (UBERON:0000956), corpus callosum (UBERON:0002336), peripheral nerves (UBERON:0001021)
• Body systems: Nervous system (motor and sensory), musculoskeletal system, urinary system

Tissue and Cell Level

• Tissues: White matter tracts (corticospinal tracts, posterior columns), cerebral and cerebellar white matter, myelin
• Cell types: Upper motor neurons (CL:0000540), corticospinal projection neurons, oligodendrocytes (CL:0000128), astrocytes (CL:0000127), microglial cells (CL:0000129)
• Subcellular: Endoplasmic reticulum (GO:0005783), mitochondria (GO:0005739), lysosomes (GO:0005764), autophagosomes (GO:0005776), microtubules (GO:0005874), lipid droplets (GO:0005811)

Localization

Neurodegeneration is bilateral and symmetric, with greatest severity in the lumbar and thoracic spinal cord regions affecting the longest descending axons (vijayaraghavan2025roleofglial pages 2-3).

8. Temporal Development

Onset

Complex HSP typically has an earlier onset than pure HSP. In pediatric cohorts, median onset is 16–24 months (ikeda2023geneticandclinical pages 3-4, saffari2023theclinicaland pages 1-2). Onset patterns include congenital/neonatal, infantile, childhood, adolescent, and adult, with some subtypes (SPG7) presenting predominantly in adulthood (fereshtehnejad2023movementdisordersin pages 5-6). Onset is typically insidious and chronic.

Progression

Disease progression is chronic and progressive. Mean annual SPRS progression is 0.9 points overall, with complicated HSP progressing at 1.3 points/year vs. 0.6 points/year for pure HSP (amprosi2026naturalhistoryin pages 1-2, amprosi2026naturalhistoryin pages 13-14). For SPG15, wheelchair dependency develops by a mean age of 20 years (saffari2023theclinicaland pages 8-9). The disease course is progressive without remission; gait impairment, cognitive decline, and autonomic dysfunction worsen over time (saffari2023theclinicaland pages 1-2, saffari2023theclinicaland pages 8-9). Significant diagnostic delay exists (median 14.4 years in SPG15) (saffari2023theclinicaland pages 3-5).

9. Inheritance and Population

Epidemiology

Global HSP prevalence ranges from 0.1 to 9.6 per 100,000, with most estimates between 1 and 5 per 100,000 (meyyazhagan2022thepuzzleof pages 1-2, yu2023clinicalfeaturesand pages 1-2, meyyazhagan2022hereditaryspasticparaplegia pages 1-2). Prevalence varies by geographic region, with higher rates reported in some European populations.

Inheritance Patterns

• Autosomal dominant: ~75–80% of registered HSP cases in Northern Europe and North America (predominantly pure forms) (meyyazhagan2022hereditaryspasticparaplegia pages 2-4, meyyazhagan2022hereditaryspasticparaplegia pages 12-14)
• Autosomal recessive: Most complex HSP forms; predominant in consanguineous populations (meyyazhagan2022hereditaryspasticparaplegia pages 12-14, fereshtehnejad2023movementdisordersin pages 4-5)
• X-linked recessive: SPG1 (L1CAM), SPG2 (PLP1) (meyyazhagan2022hereditaryspasticparaplegia pages 12-14)
• Mitochondrial: Rare forms (meyyazhagan2022hereditaryspasticparaplegia pages 2-4)

Population Demographics

AR complex HSP is more common in populations with high rates of consanguinity, such as the MENA region (meyyazhagan2022thepuzzleof pages 1-2). The male:female ratio in one Austrian cohort was approximately 64.3% male (amprosi2026naturalhistoryin pages 1-2). Approximately 40% of HSP cases present as sporadic forms without family history (meyyazhagan2022hereditaryspasticparaplegia pages 1-2).

Founder Effects

Specific variants show geographic clustering; SPG11 is the most common AR HSP gene in Iran and Tunisia (meyyazhagan2022thepuzzleof pages 1-2). Genetic diversity and distinct variant spectra have been reported in African, Asian, and European populations (meyyazhagan2022hereditaryspasticparaplegia pages 12-14).

10. Diagnostics

Clinical Tests

• Laboratory tests: Routine blood tests, serum homocysteine analysis; oxysterol levels (25- and 27-hydroxycholesterol) for SPG5 (chen2022geneticoriginof pages 1-2, meyyazhagan2022thepuzzleof pages 11-12)
• Electrophysiology: Nerve conduction studies and EMG (revealing sensorimotor polyneuropathy in some forms), somatosensory evoked potentials (chen2022geneticoriginof pages 1-2, chojdakłukasiewicz2023hereditaryspasticparaplegia pages 2-4)
• Neuroimaging: Brain MRI showing thin corpus callosum (hallmark of SPG11/SPG15), periventricular white matter changes, "ears of the lynx" sign (T2-FLAIR hyperintensity in forceps minor), cerebellar and cortical atrophy (saffari2023theclinicaland pages 3-5, chojdakłukasiewicz2023hereditaryspasticparaplegia pages 2-4, chojdakłukasiewicz2023hereditaryspasticparaplegia pages 4-6). Spinal cord MRI may show thinning (meyyazhagan2022thepuzzleof pages 5-6).
• Biomarkers: Neurofilament light chain (NfL) in plasma and CSF shows significant elevation in HSP patients and correlates inversely with age in SPG15 (saffari2023theclinicaland pages 1-2, cipriano2025fluidbiomarkersin pages 1-2, cipriano2025fluidbiomarkersin pages 12-14). GFAP, brain-derived tau, and sTREM2 are emerging biomarkers reflecting neurodegeneration and glial activation (cipriano2025fluidbiomarkersin pages 12-14).

Genetic Testing

• Recommended approach: Next-generation sequencing (NGS) gene panels targeting HSP-associated genes, with MLPA for detection of exon deletions/duplications (especially for SPAST/SPG4) (meyyazhagan2022thepuzzleof pages 5-6)
• Whole exome/genome sequencing: Employed when targeted panels are uninformative or phenotype is atypical (chojdakłukasiewicz2023hereditaryspasticparaplegia pages 4-6)
• Diagnostic yield: 45% in pure-type and 81% in complex-type pediatric-onset HSP by comprehensive genetic testing (ikeda2023geneticandclinical pages 3-4); overall genetic diagnostic rate of 35–54% across cohorts (yu2023clinicalfeaturesand pages 1-2, amprosi2026naturalhistoryin pages 1-2)
• Variant interpretation: ACMG-AMP 2015 guidelines with tools such as VarSome and InterVar (saffari2023theclinicaland pages 13-13)

Clinical Criteria

Diagnosis requires bilateral lower-limb spasticity with hyperreflexia and extensor plantar responses, without acquired causes, confirmed by at least two neurologists (chen2022geneticoriginof pages 1-2). Differential diagnosis includes cerebral palsy, ALS, leukodystrophy, hereditary ataxias, vitamin B12/copper deficiency, and arteriovenous fistulas (meyyazhagan2022thepuzzleof pages 5-6).

11. Outcome/Prognosis

Survival and Morbidity

HSP generally does not reduce lifespan in pure forms, but complex forms—particularly SPG11—may be associated with restricted life expectancy (chojdakłukasiewicz2023hereditaryspasticparaplegia pages 4-6, awuah2024hereditaryspasticparaplegia pages 1-2). The primary morbidity is progressive disability: 17.5% of patients in one cohort were wheelchair-bound, and 33% of SPG15 patients were unable to walk independently (amprosi2026naturalhistoryin pages 11-13, saffari2023theclinicaland pages 3-5).

Disease Severity Measures

Mean baseline SPRS score was 18.2 points in an Austrian cohort (consistent with European cohorts of 17.4–19.9) (amprosi2026naturalhistoryin pages 11-13). Complex HSP patients show higher SPRS scores (27.4 ± 8.9 vs. 16.7 ± 8.6 for pure HSP), indicating greater neurological impairment (siow2023outcomemeasuresand pages 2-3). In SPG15, mean SPRS was 25.2 ± 13.3 (saffari2023theclinicaland pages 6-8).

Prognostic Factors

Earlier disease onset correlates with longer diagnostic delay and disease duration but is associated with a lower risk of independent ambulation loss (yu2023clinicalfeaturesand pages 1-2). Disease duration is the strongest predictor of SPRS progression (amprosi2026naturalhistoryin pages 13-14). NfL levels may serve as prognostic biomarkers, showing correlation with disease activity (cipriano2025fluidbiomarkersin pages 12-14).

12. Treatment

Pharmacotherapy (MAXO:0000058 – pharmacotherapy)

• Antispasticity agents: Baclofen (oral and intrathecal), tizanidine, and oxybutynin (meyyazhagan2022hereditaryspasticparaplegia pages 16-18). Intrathecal baclofen (ITB) demonstrated sustained improvement in spasticity for 2–3 years followed by stable ambulatory function for 4–5 years (awuah2024hereditaryspasticparaplegia pages 12-13).
• Botulinum toxin type A: Multiple open-label studies demonstrate improvement in motor and non-motor symptoms, with improved gait velocity at follow-up (meyyazhagan2022hereditaryspasticparaplegia pages 25-25, meyyazhagan2022thepuzzleof pages 6-9). MAXO:0000087 (botulinum toxin injection).
• Dalfampridine: A potassium channel blocker explored in a pilot trial (NCT05613114) (meyyazhagan2022hereditaryspasticparaplegia pages 25-25).
• Levodopa: Explored for parkinsonism features, particularly in SPG7 and SPG11, though evidence remains limited (awuah2024hereditaryspasticparaplegia pages 12-13).

Rehabilitation (MAXO:0000011 – physical therapy)

• Physical therapy: Core management approach including stretching, balance training, and strengthening exercises (meyyazhagan2022thepuzzleof pages 6-9)
• Robot-assisted gait training: Shows promise for improving gait velocity (meyyazhagan2022thepuzzleof pages 14-15)
• Hydrotherapy and electrostimulation: Potential to increase lower extremity strength and decrease spasticity (meyyazhagan2022thepuzzleof pages 14-15)
• Ankle-foot orthoses: For mobility improvement (meyyazhagan2022hereditaryspasticparaplegia pages 16-18)

Advanced Therapeutics: Gene Therapy

A landmark single-patient phase 1 clinical trial of AAV gene therapy for SPG50 (AP4M1 gene replacement) was reported in 2024. An adeno-associated virus vector carrying the AP4M1 gene was administered intrathecally to a 4-year-old patient, showing good tolerability with no serious adverse events at 12 months and preliminary evidence of disease stabilization (dowling2024aavgenetherapy pages 1-2). Preclinical studies in Ap4m1-knockout mice demonstrated age- and dose-dependent therapeutic effects (chen2023intrathecalaav9ap4m1gene pages 1-2). Gene replacement therapy for SPG47 (AP4B1) has completed IND-enabling studies with acceptable safety profiles in nonhuman primates (wiseman2024preclinicaldevelopmentof pages 13-15). Additional experimental approaches include spastin recovery through preventing neddylation-dependent degradation, and mRNA-based therapies for SPG5 (awuah2024hereditaryspasticparaplegia pages 20-20).

Surgical Interventions (MAXO:0000004 – surgical procedure)

• Selective dorsal rhizotomy: Explored in children with limited evidence (meyyazhagan2022thepuzzleof pages 6-9)
• Spinal cord stimulation: Under investigation (NCT05196178)

Neuromodulation

Repetitive transcranial magnetic stimulation and transcutaneous spinal direct current stimulation have been explored with mixed results (awuah2024hereditaryspasticparaplegia pages 20-20, awuah2024hereditaryspasticparaplegia pages 19-20).

Clinical Trials

The following table summarizes active and recent clinical trials in HSP:

Table: This table summarizes active and recent clinical studies in hereditary spastic paraplegia, including observational natural-history efforts, rehabilitation trials, and emerging gene therapy. It is useful for identifying current trial readiness and intervention development across the HSP field.

The Spastic Paraplegia–Centers of Excellence Research Network (SP-CERN) has been established across 11 US institutions to promote clinical trial readiness through standardized clinical assessments, biorepository development, and natural history data collection (OpenTargets Search: hereditary spastic paraplegia).

13. Prevention

Primary Prevention

No primary prevention strategies exist for complex HSP given its monogenic genetic etiology. Risk reduction focuses on genetic counseling and family planning.

Genetic Counseling and Screening (MAXO:0000015 – genetic counseling)

• Carrier screening: Relevant for AR forms, particularly in consanguineous populations
• Prenatal testing: Available when the familial variant is known
• Preimplantation genetic diagnosis: An option for families with known pathogenic variants
• Cascade genetic testing: Recommended for at-risk family members

Tertiary Prevention

Management of complications through regular physiotherapy, assistive devices, and symptomatic medications can delay functional decline and improve quality of life (meyyazhagan2022thepuzzleof pages 6-9, amprosi2026naturalhistoryin pages 11-13).

14. Other Species / Natural Disease

Complex HSP is a human-specific clinical entity. No naturally occurring disease equivalent has been described in animals. However, loss-of-function mutations in orthologous genes cause motor phenotypes in model organisms (see Section 15).

15. Model Organisms

Mouse Models

Mouse models have been created for multiple HSP genes but frequently fail to fully recapitulate human motor phenotypes (damiani2024pluripotentstemcells pages 2-3, damiani2024pluripotentstemcells pages 1-2). ZFYVE26 knockout mice develop late-onset spastic paraplegia and cerebellar ataxia with neurodegeneration features at 16 months (garg2023zebrafishasa pages 25-28). Spastin knockout mice show gait abnormalities and disrupted anterograde mitochondrial transport (garg2023zebrafishasa pages 25-28). Ap4m1-KO mice treated with AAV9/AP4M1 showed age- and dose-dependent therapeutic benefits, validating gene therapy approaches (chen2023intrathecalaav9ap4m1gene pages 1-2). CRISPR-Cas9 knock-in rat models display progressive motor deficits, corpus callosum thinning, and hind limb spasticity (damiani2024pluripotentstemcells pages 6-7).

Zebrafish Models (NCBI Taxon: 7955)

Over 40 zebrafish studies have been published on HSP research (garg2024divingdeepzebrafish pages 5-6). While zebrafish lack a corticospinal tract, they demonstrate key pathological features including impaired locomotion, disrupted motor axon growth, and axonal transport defects (garg2024divingdeepzebrafish pages 5-6). Spastizin mutant zebrafish show M-cell degeneration, axon demyelination, and impaired locomotion (garg2023zebrafishasa pages 25-28). AMFR-deficient zebrafish exhibit altered touch-evoked escape response and motor neuron branching defects, which were rescued by FDA-approved statins (garg2024divingdeepzebrafish pages 5-6). Zebrafish are valued for high-throughput drug screening and optical transparency during development (garg2023zebrafishasa pages 25-28).

Drosophila Models (NCBI Taxon: 7227)

Eighteen orthologous SPG genes have been identified in Drosophila, including SPAST, ATL1, and SPG7 (vivarelli2025wingsofdiscovery pages 5-7). Loss of spas (Drosophila spastin ortholog) causes progressive movement defects, neuronal apoptosis, and immobility (vivarelli2025wingsofdiscovery pages 5-7). KIF5A mutation models faithfully reproduced axonal transport impairment, axonal swellings, and motor deficits (vivarelli2025wingsofdiscovery pages 19-20). Drosophila offers genetic tractability, rapid life cycle, and neuromuscular junction assays for phenotypic evaluation (vivarelli2025wingsofdiscovery pages 3-5).

iPSC Models

Patient-derived induced pluripotent stem cells have emerged as the most promising human cellular model for HSP (damiani2024pluripotentstemcells pages 1-2). iPSC-derived neurons faithfully mimic HSP in vitro, displaying morphological and molecular properties relevant to disease including mitochondrial dysfunction and axonal degeneration (damiani2024pluripotentstemcells pages 1-2, vivarelli2025wingsofdiscovery pages 19-20). iPSC-derived astrocytes from HSP patients show impaired lipid metabolism and reduced lipid droplet size (vijayaraghavan2025roleofglial pages 2-3). Three-dimensional organoid structures from iPSCs offer improved complexity for disease modeling and personalized medicine approaches (damiani2024pluripotentstemcells pages 6-7).

Integrated Approach

A complementary multi-model strategy has been advocated: Drosophila for high-speed genetic analysis, mice for behavioral and systemic validation, zebrafish for high-throughput drug screening, and human iPSC cultures for mechanistic studies in the patient's genetic background (vivarelli2025wingsofdiscovery pages 19-20).

Summary

Complex hereditary spastic paraplegia is a genetically heterogeneous group of Mendelian neurodegenerative disorders characterized by progressive corticospinal tract degeneration with additional neurological features. Over 90 genetic loci have been identified, with SPG11, SPG15, SPG7, and AP-4 complex genes (SPG47, SPG50, SPG51, SPG52) representing the most significant complex HSP subtypes. The pathophysiology involves convergent disruption of ER morphogenesis, autophagy-lysosomal pathways, mitochondrial function, lipid metabolism, and axonal transport. Disease management remains primarily symptomatic, but the field is entering a transformative era with the first AAV gene therapy clinical trial for SPG50 demonstrating safety and preliminary efficacy. Large-scale natural history studies and research networks such as SP-CERN are building clinical trial readiness across the HSP community. Fluid biomarkers including neurofilament light chain show promise for disease monitoring and clinical trial endpoints.

References

1. (meyyazhagan2022thepuzzleof pages 1-2): Arun Meyyazhagan, Haripriya Kuchi Bhotla, Manikantan Pappuswamy, and Antonio Orlacchio. The puzzle of hereditary spastic paraplegia: from epidemiology to treatment. International Journal of Molecular Sciences, 23:7665, Jul 2022. URL: https://doi.org/10.3390/ijms23147665, doi:10.3390/ijms23147665. This article has 60 citations.

2. (meyyazhagan2022hereditaryspasticparaplegia pages 1-2): Arun Meyyazhagan and Antonio Orlacchio. Hereditary spastic paraplegia: an update. International Journal of Molecular Sciences, 23:1697, Feb 2022. URL: https://doi.org/10.3390/ijms23031697, doi:10.3390/ijms23031697. This article has 192 citations.

3. (amprosi2026naturalhistoryin pages 1-2): Matthias Amprosi, Elisabetta Indelicato, Andreas Eigentler, Daniel Boesch, Josef Fritz, Wolfgang Nachbauer, and Sylvia Boesch. Natural history in hereditary spastic paraplegias: real-world data from an austrian cohort. Journal of Neurology, Jan 2026. URL: https://doi.org/10.1007/s00415-025-13606-y, doi:10.1007/s00415-025-13606-y. This article has 0 citations and is from a domain leading peer-reviewed journal.

4. (OpenTargets Search: hereditary spastic paraplegia): Open Targets Query (hereditary spastic paraplegia, 32 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

5. (yu2023clinicalfeaturesand pages 1-2): Weiyi Yu, Ji He, Xiangyi Liu, Jieying Wu, Xiying Cai, Yingshuang Zhang, Xiaoxuan Liu, and Dongsheng Fan. Clinical features and genetic spectrum of chinese patients with hereditary spastic paraplegia: a 14-year study. Frontiers in Genetics, Feb 2023. URL: https://doi.org/10.3389/fgene.2023.1085442, doi:10.3389/fgene.2023.1085442. This article has 7 citations and is from a peer-reviewed journal.

6. (meyyazhagan2022hereditaryspasticparaplegia pages 2-4): Arun Meyyazhagan and Antonio Orlacchio. Hereditary spastic paraplegia: an update. International Journal of Molecular Sciences, 23:1697, Feb 2022. URL: https://doi.org/10.3390/ijms23031697, doi:10.3390/ijms23031697. This article has 192 citations.

7. (cipriano2025fluidbiomarkersin pages 1-2): Lorenzo Cipriano, Nunzio Setola, Melissa Barghigiani, and Filippo Maria Santorelli. Fluid biomarkers in hereditary spastic paraplegia: a narrative review and integrative framework for complex neurodegenerative mechanisms. Genes, 16:1189, Oct 2025. URL: https://doi.org/10.3390/genes16101189, doi:10.3390/genes16101189. This article has 2 citations.

8. (fereshtehnejad2023movementdisordersin pages 4-5): Seyed-Mohammad Fereshtehnejad, Philip A. Saleh, Lais M. Oliveira, Neha Patel, Suvorit Bhowmick, Gerard Saranza, and Lorraine V. Kalia. Movement disorders in hereditary spastic paraplegia (hsp): a systematic review and individual participant data meta-analysis. Neurological Sciences, 44:947-959, Nov 2023. URL: https://doi.org/10.1007/s10072-022-06516-8, doi:10.1007/s10072-022-06516-8. This article has 18 citations and is from a peer-reviewed journal.

9. (fereshtehnejad2023movementdisordersin pages 5-6): Seyed-Mohammad Fereshtehnejad, Philip A. Saleh, Lais M. Oliveira, Neha Patel, Suvorit Bhowmick, Gerard Saranza, and Lorraine V. Kalia. Movement disorders in hereditary spastic paraplegia (hsp): a systematic review and individual participant data meta-analysis. Neurological Sciences, 44:947-959, Nov 2023. URL: https://doi.org/10.1007/s10072-022-06516-8, doi:10.1007/s10072-022-06516-8. This article has 18 citations and is from a peer-reviewed journal.

10. (saffari2023theclinicaland pages 3-5): Afshin Saffari, Melanie Kellner, Catherine Jordan, Helena Rosengarten, Alisa Mo, Bo Zhang, Oleksandr Strelko, Sonja Neuser, Marie Y Davis, Nobuaki Yoshikura, Naonobu Futamura, Tomoya Takeuchi, Shin Nabatame, Hiroyuki Ishiura, Shoji Tsuji, Huda Shujaa Aldeen, Elisa Cali, Clarissa Rocca, Henry Houlden, Stephanie Efthymiou, Birgit Assmann, Grace Yoon, Bianca A Trombetta, Pia Kivisäkk, Florian Eichler, Haitian Nan, Yoshihisa Takiyama, Alessandra Tessa, Filippo M Santorelli, Mustafa Sahin, Craig Blackstone, Edward Yang, Rebecca Schüle, and Darius Ebrahimi-Fakhari. The clinical and molecular spectrum of zfyve26-associated hereditary spastic paraplegia: spg15. Brain : a journal of neurology, 146:2003-2015, Oct 2023. URL: https://doi.org/10.1093/brain/awac391, doi:10.1093/brain/awac391. This article has 25 citations.

11. (saffari2023theclinicaland pages 1-2): Afshin Saffari, Melanie Kellner, Catherine Jordan, Helena Rosengarten, Alisa Mo, Bo Zhang, Oleksandr Strelko, Sonja Neuser, Marie Y Davis, Nobuaki Yoshikura, Naonobu Futamura, Tomoya Takeuchi, Shin Nabatame, Hiroyuki Ishiura, Shoji Tsuji, Huda Shujaa Aldeen, Elisa Cali, Clarissa Rocca, Henry Houlden, Stephanie Efthymiou, Birgit Assmann, Grace Yoon, Bianca A Trombetta, Pia Kivisäkk, Florian Eichler, Haitian Nan, Yoshihisa Takiyama, Alessandra Tessa, Filippo M Santorelli, Mustafa Sahin, Craig Blackstone, Edward Yang, Rebecca Schüle, and Darius Ebrahimi-Fakhari. The clinical and molecular spectrum of zfyve26-associated hereditary spastic paraplegia: spg15. Brain : a journal of neurology, 146:2003-2015, Oct 2023. URL: https://doi.org/10.1093/brain/awac391, doi:10.1093/brain/awac391. This article has 25 citations.

12. (chojdakłukasiewicz2023hereditaryspasticparaplegia pages 4-6): Justyna Chojdak-Łukasiewicz, Katarzyna Sulima, Anna Zimny, Marta Waliszewska-Prosół, and Sławomir Budrewicz. Hereditary spastic paraplegia type 11—clinical, genetic and neuroimaging characteristics. International Journal of Molecular Sciences, 24:17530, Dec 2023. URL: https://doi.org/10.3390/ijms242417530, doi:10.3390/ijms242417530. This article has 8 citations.

13. (chojdakłukasiewicz2023hereditaryspasticparaplegia pages 2-4): Justyna Chojdak-Łukasiewicz, Katarzyna Sulima, Anna Zimny, Marta Waliszewska-Prosół, and Sławomir Budrewicz. Hereditary spastic paraplegia type 11—clinical, genetic and neuroimaging characteristics. International Journal of Molecular Sciences, 24:17530, Dec 2023. URL: https://doi.org/10.3390/ijms242417530, doi:10.3390/ijms242417530. This article has 8 citations.

14. (saffari2023theclinicaland pages 6-8): Afshin Saffari, Melanie Kellner, Catherine Jordan, Helena Rosengarten, Alisa Mo, Bo Zhang, Oleksandr Strelko, Sonja Neuser, Marie Y Davis, Nobuaki Yoshikura, Naonobu Futamura, Tomoya Takeuchi, Shin Nabatame, Hiroyuki Ishiura, Shoji Tsuji, Huda Shujaa Aldeen, Elisa Cali, Clarissa Rocca, Henry Houlden, Stephanie Efthymiou, Birgit Assmann, Grace Yoon, Bianca A Trombetta, Pia Kivisäkk, Florian Eichler, Haitian Nan, Yoshihisa Takiyama, Alessandra Tessa, Filippo M Santorelli, Mustafa Sahin, Craig Blackstone, Edward Yang, Rebecca Schüle, and Darius Ebrahimi-Fakhari. The clinical and molecular spectrum of zfyve26-associated hereditary spastic paraplegia: spg15. Brain : a journal of neurology, 146:2003-2015, Oct 2023. URL: https://doi.org/10.1093/brain/awac391, doi:10.1093/brain/awac391. This article has 25 citations.

15. (ikeda2023geneticandclinical pages 3-4): Azusa Ikeda, Tatsuro Kumaki, Yu Tsuyusaki, Megumi Tsuji, Yumi Enomoto, Atsushi Fujita, Hirotomo Saitsu, Naomichi Matsumoto, Kenji Kurosawa, and Tomohide Goto. Genetic and clinical features of pediatric-onset hereditary spastic paraplegia: a single-center study in japan. Frontiers in Neurology, May 2023. URL: https://doi.org/10.3389/fneur.2023.1085228, doi:10.3389/fneur.2023.1085228. This article has 6 citations and is from a peer-reviewed journal.

16. (awuah2024hereditaryspasticparaplegia pages 8-10): Wireko Andrew Awuah, Joecelyn Kirani Tan, Anastasiia D Shkodina, Tomas Ferreira, Favour Tope Adebusoye, Adele Mazzoleni, Jack Wellington, Lian David, Ellie Chilcott, Helen Huang, Toufik Abdul-Rahman, Vallabh Shet, Oday Atallah, Jacob Kalmanovich, Riaz Jiffry, Divine Elizabeth Madhu, Kateryna Sikora, Oleksii Kmyta, and Mykhailo Yu Delva. Hereditary spastic paraplegia: novel insights into the pathogenesis and management. SAGE Open Medicine, Dec 2024. URL: https://doi.org/10.1177/20503121231221941, doi:10.1177/20503121231221941. This article has 31 citations.

17. (dowling2024aavgenetherapy pages 1-2): James J. Dowling, Terry Pirovolakis, Keshini Devakandan, Ana Stosic, Mia Pidsadny, Elisa Nigro, Mustafa Sahin, Darius Ebrahimi-Fakhari, Souad Messahel, Ganapathy Varadarajan, Benjamin M. Greenberg, Xin Chen, Berge A. Minassian, Ronald Cohn, Carsten G. Bonnemann, and Steven J. Gray. Aav gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient. Nature Medicine, 30:1882-1887, Jun 2024. URL: https://doi.org/10.1038/s41591-024-03078-4, doi:10.1038/s41591-024-03078-4. This article has 40 citations and is from a highest quality peer-reviewed journal.

18. (saffari2023theclinicaland pages 8-9): Afshin Saffari, Melanie Kellner, Catherine Jordan, Helena Rosengarten, Alisa Mo, Bo Zhang, Oleksandr Strelko, Sonja Neuser, Marie Y Davis, Nobuaki Yoshikura, Naonobu Futamura, Tomoya Takeuchi, Shin Nabatame, Hiroyuki Ishiura, Shoji Tsuji, Huda Shujaa Aldeen, Elisa Cali, Clarissa Rocca, Henry Houlden, Stephanie Efthymiou, Birgit Assmann, Grace Yoon, Bianca A Trombetta, Pia Kivisäkk, Florian Eichler, Haitian Nan, Yoshihisa Takiyama, Alessandra Tessa, Filippo M Santorelli, Mustafa Sahin, Craig Blackstone, Edward Yang, Rebecca Schüle, and Darius Ebrahimi-Fakhari. The clinical and molecular spectrum of zfyve26-associated hereditary spastic paraplegia: spg15. Brain : a journal of neurology, 146:2003-2015, Oct 2023. URL: https://doi.org/10.1093/brain/awac391, doi:10.1093/brain/awac391. This article has 25 citations.

19. (amprosi2026naturalhistoryin pages 13-14): Matthias Amprosi, Elisabetta Indelicato, Andreas Eigentler, Daniel Boesch, Josef Fritz, Wolfgang Nachbauer, and Sylvia Boesch. Natural history in hereditary spastic paraplegias: real-world data from an austrian cohort. Journal of Neurology, Jan 2026. URL: https://doi.org/10.1007/s00415-025-13606-y, doi:10.1007/s00415-025-13606-y. This article has 0 citations and is from a domain leading peer-reviewed journal.

20. (amprosi2026naturalhistoryin pages 11-13): Matthias Amprosi, Elisabetta Indelicato, Andreas Eigentler, Daniel Boesch, Josef Fritz, Wolfgang Nachbauer, and Sylvia Boesch. Natural history in hereditary spastic paraplegias: real-world data from an austrian cohort. Journal of Neurology, Jan 2026. URL: https://doi.org/10.1007/s00415-025-13606-y, doi:10.1007/s00415-025-13606-y. This article has 0 citations and is from a domain leading peer-reviewed journal.

21. (awuah2024hereditaryspasticparaplegia pages 1-2): Wireko Andrew Awuah, Joecelyn Kirani Tan, Anastasiia D Shkodina, Tomas Ferreira, Favour Tope Adebusoye, Adele Mazzoleni, Jack Wellington, Lian David, Ellie Chilcott, Helen Huang, Toufik Abdul-Rahman, Vallabh Shet, Oday Atallah, Jacob Kalmanovich, Riaz Jiffry, Divine Elizabeth Madhu, Kateryna Sikora, Oleksii Kmyta, and Mykhailo Yu Delva. Hereditary spastic paraplegia: novel insights into the pathogenesis and management. SAGE Open Medicine, Dec 2024. URL: https://doi.org/10.1177/20503121231221941, doi:10.1177/20503121231221941. This article has 31 citations.

22. (vijayaraghavan2025roleofglial pages 2-3): Manaswini Vijayaraghavan, Sarvika Periyapalayam Murali, Gitika Thakur, and Xue-Jun Li. Role of glial cells in motor neuron degeneration in hereditary spastic paraplegias. Frontiers in Cellular Neuroscience, Apr 2025. URL: https://doi.org/10.3389/fncel.2025.1553658, doi:10.3389/fncel.2025.1553658. This article has 3 citations.

23. (meyyazhagan2022hereditaryspasticparaplegia pages 12-14): Arun Meyyazhagan and Antonio Orlacchio. Hereditary spastic paraplegia: an update. International Journal of Molecular Sciences, 23:1697, Feb 2022. URL: https://doi.org/10.3390/ijms23031697, doi:10.3390/ijms23031697. This article has 192 citations.

24. (chojdakłukasiewicz2023hereditaryspasticparaplegia pages 7-8): Justyna Chojdak-Łukasiewicz, Katarzyna Sulima, Anna Zimny, Marta Waliszewska-Prosół, and Sławomir Budrewicz. Hereditary spastic paraplegia type 11—clinical, genetic and neuroimaging characteristics. International Journal of Molecular Sciences, 24:17530, Dec 2023. URL: https://doi.org/10.3390/ijms242417530, doi:10.3390/ijms242417530. This article has 8 citations.

25. (wiseman2024preclinicaldevelopmentof pages 13-15): Jessica P Wiseman, Joseph M Scarrott, João Alves-Cruzeiro, Afshin Saffari, Cedric Böger, Evangelia Karyka, Emily Dawes, Alexandra K Davies, Paolo M Marchi, Emily Graves, Fiona Fernandes, Zih-Liang Yang, Ian Coldicott, Jennifer Hirst, Christopher P Webster, J Robin Highley, Neil Hackett, Adrienn Angyal, Thushan de Silva, Adrian Higginbottom, Pamela J Shaw, Laura Ferraiuolo, Darius Ebrahimi-Fakhari, and Mimoun Azzouz. Pre-clinical development of ap4b1 gene replacement therapy for hereditary spastic paraplegia type 47. EMBO Molecular Medicine, 16:2882-2917, Oct 2024. URL: https://doi.org/10.1038/s44321-024-00148-5, doi:10.1038/s44321-024-00148-5. This article has 14 citations and is from a highest quality peer-reviewed journal.

26. (chen2023intrathecalaav9ap4m1gene pages 1-2): Xin Chen, Thomas Dong, Yuhui Hu, Raffaella De Pace, Rafael Mattera, Kathrin Eberhardt, Marvin Ziegler, Terry Pirovolakis, Mustafa Sahin, Juan S. Bonifacino, Darius Ebrahimi-Fakhari, and Steven J. Gray. Intrathecal aav9/ap4m1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies. Journal of Clinical Investigation, May 2023. URL: https://doi.org/10.1172/jci164575, doi:10.1172/jci164575. This article has 54 citations and is from a highest quality peer-reviewed journal.

27. (meyyazhagan2022thepuzzleof pages 11-12): Arun Meyyazhagan, Haripriya Kuchi Bhotla, Manikantan Pappuswamy, and Antonio Orlacchio. The puzzle of hereditary spastic paraplegia: from epidemiology to treatment. International Journal of Molecular Sciences, 23:7665, Jul 2022. URL: https://doi.org/10.3390/ijms23147665, doi:10.3390/ijms23147665. This article has 60 citations.

28. (meyyazhagan2022hereditaryspasticparaplegia pages 4-6): Arun Meyyazhagan and Antonio Orlacchio. Hereditary spastic paraplegia: an update. International Journal of Molecular Sciences, 23:1697, Feb 2022. URL: https://doi.org/10.3390/ijms23031697, doi:10.3390/ijms23031697. This article has 192 citations.

29. (meyyazhagan2022hereditaryspasticparaplegia pages 20-21): Arun Meyyazhagan and Antonio Orlacchio. Hereditary spastic paraplegia: an update. International Journal of Molecular Sciences, 23:1697, Feb 2022. URL: https://doi.org/10.3390/ijms23031697, doi:10.3390/ijms23031697. This article has 192 citations.

30. (meyyazhagan2022hereditaryspasticparaplegia pages 14-16): Arun Meyyazhagan and Antonio Orlacchio. Hereditary spastic paraplegia: an update. International Journal of Molecular Sciences, 23:1697, Feb 2022. URL: https://doi.org/10.3390/ijms23031697, doi:10.3390/ijms23031697. This article has 192 citations.

31. (meyyazhagan2022thepuzzleof pages 12-14): Arun Meyyazhagan, Haripriya Kuchi Bhotla, Manikantan Pappuswamy, and Antonio Orlacchio. The puzzle of hereditary spastic paraplegia: from epidemiology to treatment. International Journal of Molecular Sciences, 23:7665, Jul 2022. URL: https://doi.org/10.3390/ijms23147665, doi:10.3390/ijms23147665. This article has 60 citations.

32. (garg2024divingdeepzebrafish pages 5-6): Vranda Garg and Bart R. H. Geurten. Diving deep: zebrafish models in motor neuron degeneration research. Frontiers in Neuroscience, Jun 2024. URL: https://doi.org/10.3389/fnins.2024.1424025, doi:10.3389/fnins.2024.1424025. This article has 10 citations and is from a peer-reviewed journal.

33. (meyyazhagan2022thepuzzleof pages 5-6): Arun Meyyazhagan, Haripriya Kuchi Bhotla, Manikantan Pappuswamy, and Antonio Orlacchio. The puzzle of hereditary spastic paraplegia: from epidemiology to treatment. International Journal of Molecular Sciences, 23:7665, Jul 2022. URL: https://doi.org/10.3390/ijms23147665, doi:10.3390/ijms23147665. This article has 60 citations.

34. (saffari2023theclinicaland pages 13-13): Afshin Saffari, Melanie Kellner, Catherine Jordan, Helena Rosengarten, Alisa Mo, Bo Zhang, Oleksandr Strelko, Sonja Neuser, Marie Y Davis, Nobuaki Yoshikura, Naonobu Futamura, Tomoya Takeuchi, Shin Nabatame, Hiroyuki Ishiura, Shoji Tsuji, Huda Shujaa Aldeen, Elisa Cali, Clarissa Rocca, Henry Houlden, Stephanie Efthymiou, Birgit Assmann, Grace Yoon, Bianca A Trombetta, Pia Kivisäkk, Florian Eichler, Haitian Nan, Yoshihisa Takiyama, Alessandra Tessa, Filippo M Santorelli, Mustafa Sahin, Craig Blackstone, Edward Yang, Rebecca Schüle, and Darius Ebrahimi-Fakhari. The clinical and molecular spectrum of zfyve26-associated hereditary spastic paraplegia: spg15. Brain : a journal of neurology, 146:2003-2015, Oct 2023. URL: https://doi.org/10.1093/brain/awac391, doi:10.1093/brain/awac391. This article has 25 citations.

35. (meyyazhagan2022thepuzzleof pages 2-5): Arun Meyyazhagan, Haripriya Kuchi Bhotla, Manikantan Pappuswamy, and Antonio Orlacchio. The puzzle of hereditary spastic paraplegia: from epidemiology to treatment. International Journal of Molecular Sciences, 23:7665, Jul 2022. URL: https://doi.org/10.3390/ijms23147665, doi:10.3390/ijms23147665. This article has 60 citations.

36. (awuah2024hereditaryspasticparaplegia pages 2-4): Wireko Andrew Awuah, Joecelyn Kirani Tan, Anastasiia D Shkodina, Tomas Ferreira, Favour Tope Adebusoye, Adele Mazzoleni, Jack Wellington, Lian David, Ellie Chilcott, Helen Huang, Toufik Abdul-Rahman, Vallabh Shet, Oday Atallah, Jacob Kalmanovich, Riaz Jiffry, Divine Elizabeth Madhu, Kateryna Sikora, Oleksii Kmyta, and Mykhailo Yu Delva. Hereditary spastic paraplegia: novel insights into the pathogenesis and management. SAGE Open Medicine, Dec 2024. URL: https://doi.org/10.1177/20503121231221941, doi:10.1177/20503121231221941. This article has 31 citations.

37. (chen2022geneticoriginof pages 1-2): Jiann-Nan Chen, Zhe Zhao, Hong-rui Shen, Qi Bing, Nan Li, Xuan Guo, and Jing Hu. Genetic origin of patients having spastic paraplegia with or without other neurologic manifestations. BMC Neurology, May 2022. URL: https://doi.org/10.1186/s12883-022-02708-z, doi:10.1186/s12883-022-02708-z. This article has 10 citations and is from a peer-reviewed journal.

38. (cipriano2025fluidbiomarkersin pages 12-14): Lorenzo Cipriano, Nunzio Setola, Melissa Barghigiani, and Filippo Maria Santorelli. Fluid biomarkers in hereditary spastic paraplegia: a narrative review and integrative framework for complex neurodegenerative mechanisms. Genes, 16:1189, Oct 2025. URL: https://doi.org/10.3390/genes16101189, doi:10.3390/genes16101189. This article has 2 citations.

39. (siow2023outcomemeasuresand pages 2-3): Sue-Faye Siow, Dennis Yeow, Laura I. Rudaks, Fangzhi Jia, Gautam Wali, Carolyn M. Sue, and Kishore R. Kumar. Outcome measures and biomarkers for clinical trials in hereditary spastic paraplegia: a scoping review. Genes, 14:1756, Sep 2023. URL: https://doi.org/10.3390/genes14091756, doi:10.3390/genes14091756. This article has 18 citations.

40. (meyyazhagan2022hereditaryspasticparaplegia pages 16-18): Arun Meyyazhagan and Antonio Orlacchio. Hereditary spastic paraplegia: an update. International Journal of Molecular Sciences, 23:1697, Feb 2022. URL: https://doi.org/10.3390/ijms23031697, doi:10.3390/ijms23031697. This article has 192 citations.

41. (awuah2024hereditaryspasticparaplegia pages 12-13): Wireko Andrew Awuah, Joecelyn Kirani Tan, Anastasiia D Shkodina, Tomas Ferreira, Favour Tope Adebusoye, Adele Mazzoleni, Jack Wellington, Lian David, Ellie Chilcott, Helen Huang, Toufik Abdul-Rahman, Vallabh Shet, Oday Atallah, Jacob Kalmanovich, Riaz Jiffry, Divine Elizabeth Madhu, Kateryna Sikora, Oleksii Kmyta, and Mykhailo Yu Delva. Hereditary spastic paraplegia: novel insights into the pathogenesis and management. SAGE Open Medicine, Dec 2024. URL: https://doi.org/10.1177/20503121231221941, doi:10.1177/20503121231221941. This article has 31 citations.

42. (meyyazhagan2022hereditaryspasticparaplegia pages 25-25): Arun Meyyazhagan and Antonio Orlacchio. Hereditary spastic paraplegia: an update. International Journal of Molecular Sciences, 23:1697, Feb 2022. URL: https://doi.org/10.3390/ijms23031697, doi:10.3390/ijms23031697. This article has 192 citations.

43. (meyyazhagan2022thepuzzleof pages 6-9): Arun Meyyazhagan, Haripriya Kuchi Bhotla, Manikantan Pappuswamy, and Antonio Orlacchio. The puzzle of hereditary spastic paraplegia: from epidemiology to treatment. International Journal of Molecular Sciences, 23:7665, Jul 2022. URL: https://doi.org/10.3390/ijms23147665, doi:10.3390/ijms23147665. This article has 60 citations.

44. (meyyazhagan2022thepuzzleof pages 14-15): Arun Meyyazhagan, Haripriya Kuchi Bhotla, Manikantan Pappuswamy, and Antonio Orlacchio. The puzzle of hereditary spastic paraplegia: from epidemiology to treatment. International Journal of Molecular Sciences, 23:7665, Jul 2022. URL: https://doi.org/10.3390/ijms23147665, doi:10.3390/ijms23147665. This article has 60 citations.

45. (awuah2024hereditaryspasticparaplegia pages 20-20): Wireko Andrew Awuah, Joecelyn Kirani Tan, Anastasiia D Shkodina, Tomas Ferreira, Favour Tope Adebusoye, Adele Mazzoleni, Jack Wellington, Lian David, Ellie Chilcott, Helen Huang, Toufik Abdul-Rahman, Vallabh Shet, Oday Atallah, Jacob Kalmanovich, Riaz Jiffry, Divine Elizabeth Madhu, Kateryna Sikora, Oleksii Kmyta, and Mykhailo Yu Delva. Hereditary spastic paraplegia: novel insights into the pathogenesis and management. SAGE Open Medicine, Dec 2024. URL: https://doi.org/10.1177/20503121231221941, doi:10.1177/20503121231221941. This article has 31 citations.

46. (awuah2024hereditaryspasticparaplegia pages 19-20): Wireko Andrew Awuah, Joecelyn Kirani Tan, Anastasiia D Shkodina, Tomas Ferreira, Favour Tope Adebusoye, Adele Mazzoleni, Jack Wellington, Lian David, Ellie Chilcott, Helen Huang, Toufik Abdul-Rahman, Vallabh Shet, Oday Atallah, Jacob Kalmanovich, Riaz Jiffry, Divine Elizabeth Madhu, Kateryna Sikora, Oleksii Kmyta, and Mykhailo Yu Delva. Hereditary spastic paraplegia: novel insights into the pathogenesis and management. SAGE Open Medicine, Dec 2024. URL: https://doi.org/10.1177/20503121231221941, doi:10.1177/20503121231221941. This article has 31 citations.

47. (damiani2024pluripotentstemcells pages 2-3): Devid Damiani, Matteo Baggiani, Stefania Della Vecchia, Valentina Naef, and Filippo Maria Santorelli. Pluripotent stem cells as a preclinical cellular model for studying hereditary spastic paraplegias. International Journal of Molecular Sciences, 25:2615, Feb 2024. URL: https://doi.org/10.3390/ijms25052615, doi:10.3390/ijms25052615. This article has 11 citations.

48. (damiani2024pluripotentstemcells pages 1-2): Devid Damiani, Matteo Baggiani, Stefania Della Vecchia, Valentina Naef, and Filippo Maria Santorelli. Pluripotent stem cells as a preclinical cellular model for studying hereditary spastic paraplegias. International Journal of Molecular Sciences, 25:2615, Feb 2024. URL: https://doi.org/10.3390/ijms25052615, doi:10.3390/ijms25052615. This article has 11 citations.

49. (garg2023zebrafishasa pages 25-28): Vranda Garg. Zebrafish as a model for hereditary spastic paraplegia. ArXiv, 2023. URL: https://doi.org/10.53846/goediss-9965, doi:10.53846/goediss-9965. This article has 0 citations.

50. (damiani2024pluripotentstemcells pages 6-7): Devid Damiani, Matteo Baggiani, Stefania Della Vecchia, Valentina Naef, and Filippo Maria Santorelli. Pluripotent stem cells as a preclinical cellular model for studying hereditary spastic paraplegias. International Journal of Molecular Sciences, 25:2615, Feb 2024. URL: https://doi.org/10.3390/ijms25052615, doi:10.3390/ijms25052615. This article has 11 citations.

51. (vivarelli2025wingsofdiscovery pages 5-7): Rachele Vivarelli, Chiara Vantaggiato, Maria Teresa Bassi, Filippo Maria Santorelli, and Maria Marchese. Wings of discovery: using drosophila to decode hereditary spastic paraplegia and ataxias. Cells, 14:1466, Sep 2025. URL: https://doi.org/10.3390/cells14181466, doi:10.3390/cells14181466. This article has 1 citations.

52. (vivarelli2025wingsofdiscovery pages 19-20): Rachele Vivarelli, Chiara Vantaggiato, Maria Teresa Bassi, Filippo Maria Santorelli, and Maria Marchese. Wings of discovery: using drosophila to decode hereditary spastic paraplegia and ataxias. Cells, 14:1466, Sep 2025. URL: https://doi.org/10.3390/cells14181466, doi:10.3390/cells14181466. This article has 1 citations.

53. (vivarelli2025wingsofdiscovery pages 3-5): Rachele Vivarelli, Chiara Vantaggiato, Maria Teresa Bassi, Filippo Maria Santorelli, and Maria Marchese. Wings of discovery: using drosophila to decode hereditary spastic paraplegia and ataxias. Cells, 14:1466, Sep 2025. URL: https://doi.org/10.3390/cells14181466, doi:10.3390/cells14181466. This article has 1 citations.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02